Clinical trialPhase 2Active not recruiting
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Sulfonylurea Safety and Effectiveness (SUSS) for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Revie
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 5 December 2023
- Expected end
- 5 December 2026
- Enrollment
- 29 participants
- Sites
- 7
- Primary outcomes
- Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 6 August 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.